---
id: 023
title: Ampicillin-Sulbactam Spectrum and Clinical Uses
category: antimicrobials
subcategory: penicillins
tags: [ampicillin-sulbactam, Unasyn, Acinetobacter, anaerobes, ABCESS]
difficulty: medium
---

## Question

What is the unique spectrum of **ampicillin-sulbactam**, and what are its main clinical uses? Use the **ABCESS** mnemonic for coverage.

## Answer

**ABCESS mnemonic for ampicillin-sulbactam coverage:**

- **A**cinetobacter baumannii (sulbactam has intrinsic activity)
- **B**acteroides/anaerobes (B. fragilis, Peptostreptococcus, Clostridium)
- **C**ommunity Gram-positives (MSSA, Streptococci, Enterococcus)
- **E**nterobacterales (E. coli, Proteus, Klebsiella - if β-lactamase producers)
- **S**kin flora (polymicrobial infections)
- **S**inusitis/oral anaerobes

### **Key Clinical Uses:**

| Indication | Rationale |
|------------|-----------|
| **Intra-abdominal infections** | Polymicrobial (aerobes + anaerobes) |
| **Aspiration pneumonia** | Oral anaerobes |
| **Diabetic foot infections** | Polymicrobial (aerobes + anaerobes) |
| **Pelvic infections** | Polymicrobial (anaerobes) |
| **Carbapenem-resistant *Acinetobacter*** | Sulbactam binds PBPs (PBP1, PBP3) |

### **Dosing:**

- **Standard:** 1.5-3g IV q6h (ampicillin 1-2g + sulbactam 0.5-1g)
- **CRAB (carbapenem-resistant *Acinetobacter*):** 9g IV q8h over 4 hours (high-dose sulbactam 3g)
- **Target:** fT>MIC >50% (time-dependent killing)

## Key Points

- **Sulbactam has intrinsic antibacterial activity** vs *Acinetobacter* (unlike other β-lactamase inhibitors)
- **Does NOT cover:** *Pseudomonas*, MRSA, atypicals
- **Preferred over pip-tazo** for polymicrobial infections WITHOUT *Pseudomonas* risk
- **2022 IDSA guidelines:** High-dose amp-sulb is preferred for CRAB

## Sources

- [StatPearls NBK526117: Ampicillin/Sulbactam]
- [2022 IDSA CRAB Guidelines]
- [J Antimicrob Chemother 2024: Amp-sulb PK/PD for Acinetobacter]

## Media

N/A
